Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3
- This topic has 0 replies, 1 voice, and was last updated 2 years, 6 months ago by
.
Viewing 1 post (of 1 total)
-
Posts
-
Design and rationale of a first-in-human (FIH) phase 1/1b study evaluating KIN-3248, a next-generation, irreversible (irrev), pan-FGFR inhibitor (FGFRi), in adult patients with solid tumors harboring FGFR2 and/or FGFR3 gene alterations (NCT05242822).
https://meetings.asco.org/abstracts-presentations/213092
Viewing 1 post (of 1 total)
- The forum ‘Clinical Trials’ is closed to new topics and replies.